Yuvimont-Plus Tablet SR is a combination medication containing Montelukast (10mg), Fexofenadine (20mg), and Acebrophylline (200mg), formulated for the management of respiratory conditions characterized by bronchoconstriction, inflammation, and allergic symptoms. Montelukast, a leukotriene receptor antagonist, effectively reduces airway inflammation and bronchospasm by blocking leukotriene receptors, thereby improving airflow in conditions such as asthma and allergic rhinitis. Fexofenadine, a second-generation antihistamine, selectively inhibits peripheral H1 receptors, providing relief from allergic symptoms including sneezing, nasal congestion, and urticaria without causing significant sedation. Acebrophylline, a bronchodilator with mucolytic and anti-inflammatory properties, facilitates bronchodilation by relaxing airway smooth muscles and enhances mucus clearance, thus improving respiratory function in obstructive airway diseases. The sustained-release formulation ensures prolonged therapeutic effect, enhancing patient compliance by reducing dosing frequency. Yuvimont-Plus Tablet SR is indicated for the treatment of chronic bronchitis, asthma, and allergic respiratory disorders where combined anti-inflammatory, bronchodilator, and antihistaminic actions are required. It should be used under medical supervision, with caution advised in patients with hepatic or renal impairment. Adverse effects are generally mild but may include headache, gastrointestinal disturbances, or dry mouth. This combination therapy offers a comprehensive approach to managing complex respiratory conditions by targeting multiple pathophysiological pathways.